APIs PIPELINE EXPANSION in OLON GROUP

 
 

As the CPhI Worldwide 2021 takes place in Milan (Italy), the largest international event dedicated to the pharmaceutical and chemical-pharmaceutical industry, the Olon Group is pleased to announce a significant expansion of its pipeline of active pharmaceutical ingredients, a result of its R&D investment strategy.

The event is representative of the pharmaceutical industry’s entire supply chain, and the producers of active substances and outsourced manufacturing — for which Olon is one of the major Italian representatives — are the "backbone".

With a global network of production sites, the Italian Group is a leader in the production of generic and CDMO APIs, for chemical as well as biological synthesis. Relying on one of the sector’s longest track records and a significant investment in R&D, at the CPhI, Olon will present a pipeline enriched with 9 new active substances for the generic market. The expansion of the pipeline — a result of continuous investment in internal R&D — represents diversification in terms of therapeutic areas and molecule types, with the introduction, for example, of new APIs in multiple sclerosis and the treatment of anaemia, as well as in terms of implementing new synthesis routes. Olon apply to development and industrial manufacturing some of the most advanced technologies, among the foremost there are biocatalysis, fluorination, cryogenic reaction and flow chemistry.

“Thanks to our experience in the generics market, we are known for our ability to adapt to specific quality, physical and chemical needs, as well as IP strategies that allow a prompt access to quality and affordable medicine generics as quickly as possible” commented Paolo Tubertini, CEO at Olon Group.

Olon has diversified and backed investments across several lines and multiple facilities to be able to manage various high-containment molecules at different scales and guarantee flexibility on a significant scale.

Olon’s pipeline of generic APIs is reinforced in the oncology area, where the Group has solid expertise as one of the sector’s top companies producing high-activity active substances, with the introduction of numerous anti-tumour APIs, particularly those with selective high activity.